Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Hydrochloride Capsules USP

Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg, the generic version of Cleocin® Hydrochloride Capsules, 75 mg, 150 mg, and 300 mg, of Pfizer Inc. Glenmark's Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.

According to IQVIATM sales data for the 12-month period ending January 2023, the Cleocin® Hydrochloride Capsules, 75 mg, 150 mg, and 300 mg market2 achieved annual sales of approximately $33.6 million*.

Glenmark's current portfolio consists of 181 products authorized for distribution in the U.S. marketplace and 47 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 425.60 as compared to the previous close of Rs. 428.90. The total number of shares traded during the day was 33196 in over 1544 trades.

The stock hit an intraday high of Rs. 431.70 and intraday low of 424.05. The net turnover during the day was Rs. 14150367.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 FinalApproval USFDA ClindamycinHydrochlorideCapsules